Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 87-94

  van Houtum, W H ^a   Corssmit, E P M ^a   Douwes Dekker, P B ^a   Jansen, J C ^a   van der Mey, A G L ^a   Brocker Vriends A H J T ^a   Taschner, P E M ^a   Losekoot, M ^a   Frolich M ^a   Stokkel, M P M ^a   Cornelisse, C J ^a   Romijn, J A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CATECHOLAMINE; SUCCINATE DEHYDROGENASE;

ADULT; ALLELE; ANAMNESIS; ARTICLE; CATECHOLAMINE EXCRETION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC LINKAGE; HEAD AND NECK TUMOR; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIFESPAN; MALE; MEDICAL DOCUMENTATION; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; SCREENING TEST; TUMOR LOCALIZATION; UNIVERSITY HOSPITAL; URINALYSIS; WILD TYPE;

ADRENAL GLAND NEOPLASMS; ADULT; CATECHOLAMINES; COHORT STUDIES; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HEAD AND NECK NEOPLASMS; HUMANS; IMIDAZOLES; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE;

EID: 19944431652     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01833     Document Type: Article

References (36)

1. Zak FG & Lawson W. The Paraganglionic Chemoreceptor System New York: Springer Verlag, 1982.
2. Lack EE. Tumors of the Adrenal Gland & Extra-Adrenal Paraganglia. Washington, DC: Armed Forces Institute of Pathology, 1997.
3. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA & Young WF. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. Journal of Clinical Endocrinology and Metabolism 2004 86 5210-5216.
4. Bravo EL & Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocrine Reviews 2003 24 539-553.
5. Drovdlic CM, Myers EN, Peters JA, Baysal BE, Brackmann DE, Slattery WH III & Rubinstein WS. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 2001 111 1822-1827.
6. Grufferman S, Gillman MW, Pasternak LR, Peterson CL & Young WG Jr. Familial carotid body tumors: case report and epidemiologic review. Cancer 1980 46 2116-2122.
7. Sugarbaker EV, Chretien PB & Jacobs JB. Bilateral familial carotid body tumors: report of a patient with an occult contralateral tumor and postoperative hypertension. Annals of Surgery 1971 174 242-247.
8. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. Journal of Medical Genetics 2002 39 617-622.
9. van Schothorst EM, Beekman M, Torremans P, Kuipers-Dijkshoorn NJ, Wessels HW, Bardoel AF, van der Mey AG, van der Vijver MJ, van Ommen GJ, Devilee P & Cornelisse CJ. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Human Pathology 1998 29 1045-1049.
10. Gimm O, Armanios M, Dziema H, Neumann HP & Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research 2000 60 6822-6825.
11. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, Delbridge L, Pollan PT, Hammond J, Marsh DJ & Robinson BG. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 2003 22 1358-1364.
12. Mariman EC, van Beersum SE, Cremers CW, van Baars FM & Ropers HH. Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q. Human Genetics 1993 91 357-361.
13. van Schothorst EM, Jansen JC, Grooters E, Prins DE, Wiersinga JJ, van der Mey AG, van Ommen GJ, Devilee P & Cornelisse CJ. Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. American Journal of Human Genetics 1998 63 468-473.
14. Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Brocker-Vriends AH, Der Mey AG, van Ommen GJ, Cornelisse CJ & Devilee P. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes, Chromosomes & Cancer 2001 31 274-281.
15. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F & Maher ER. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001 357 1181-1182.
16. Young AL, Baysal BE, Deb A & Young WF Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. Journal of Clinical Endocrinology and Metabolism 2002 87 4101-4105.
17. Heinemann G, Schievelbein H, Eberhagen D & Rahlfs V. The influence of different diets and smoking on the clinical chemical diagnosis of pheochromocytoma, neuroblastoma, and carcinoid syndrome [in German]. Klinischer Wochenschrift 1981 59 1165-1173.
18. Burtis CA & Ashwood ER. Tietz Textbook of Clinical Chemistry. Philadelphia: Saunders, 1994.
19. Kagedal B & Goldstein DS. Catecholamines and their metabolites. Journal of Chromatography 1988 429 177-233.
20. Graham PE, Smythe GA, Edwards GA & Lazarus L. Laboratory diagnosis of phaeochromocytoma: which analytes should we measure? Annals of Clinical Biochemistry 1993 30 129-134.
21. Douwes Dekker PB, Kuipers-Dijkshoorn N, Hogendoorn PC, van der Mey AG & Cornelisse CJ. G2M arrest, blocked apoptosis, and low growth fraction may explain indolent behavior of head and neck paragangliomas. Human Pathology 2003 34 690-698.
22. Abeln EC, Corver WE, Kuipers-Dijkshoorn NJ, Fleuren GJ & Cornelisse CJ. Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity. British Journal of Cancer 1994 70 255-262.
23. SPSS. SPSS for Windows. Chicago: SPSS, 1999.
24. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association 2002 287 1427-1434.
25. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C & Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics 2001 69 49-54.
26. Jensen JC, Choyke PL, Rosenfeld M, Pass HI, Keiser H, White B, Travis W & Linehan WM. A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. Journal of Urology 1991 145 1040-1042.
27. Pritchett JW. Familial concurrence of carotid body tumor and pheochromocytoma. Cancer 1982 49 2578-2579.
28. Baysal BE, Rubinstein WS & Taschner PE. Phenotypic dichotomy in mitochondrial complex II genetic disorders. Journal of Molecular Medicine 2001 79 495-503.
29. Hensen EF, Jordanova ES, van Minderhout IJ, Hogendoorn PC, Taschner PE, van der Mey AG, Devilee P & Cornelisse CJ. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 2004 23 4076-4083.
30. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW & Pacak K. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 2001 86 1999-2008.
31. Pacak K, Linehan WM, Eisenhofer G, Walther MM & Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytomas. Endocrine Reviews 2004 134 315-329.
32. Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, Schmid I & Hahn K. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. American Journal of Roentgenology 2003 181 1115-1124.
33. Honigschnabl S, Gallo S, Niederle B, Prager G, Kaserer K, Lechner G & Heinz-Peer G. How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. European Journal of Radiology 2002 41 113-122.
34. Tormey WP, Keeling F & Lee MJ. 123I-metaiodobenzylguanidine scans in phaeochromocytoma diagnosis: current clinical practice and relationship to biochemical screening. International Journal of Clinical Practice 1999 53 428-432.
35. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S & Nielsen PE. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. Journal of Human Hypertension 1988 2 187-189.
36. Sutton MG, Sheps SG & Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clinical Proceedings 1981 56 354-360.